10:00 - 12:30 Auditorium

Chair: P. Romero (Switzerland)
Chair: P.A. Ascierto (Italy)

11:00 Introduction

11:05 Cancer evasion of the immune system: the fundamentals
Speaker: P. Romero (Switzerland)

11:25 Checkpoint blockade a concept or already a reality?
Speaker: P.A. Ascierto (Italy)

11:50 Emerging pathways
Speaker: C. Holler (Austria)

12:15 Conclusions and Q and A

Plenary Session: Opening Plenary Session

13:00 - 15:00 Auditorium

Chair: H. Zwierzina (Austria)
Chair: V. Nussler (Germany)

13:00 Welcome address
Speaker: H. Zwierzina (Austria)

13:10 KEYNOTE LECTURE: Cancer immunotherapy-current and future advancements
Speaker: A.M.M. Eggermont (France)

13:40 Combinatorial Immunotherapy and Anti-angiogenic Approaches in Ovarian Cancer
Speaker: L. Kandalaft (Switzerland)
14:00  Toll like receptor 7 agonists and ligands for RIG-I for cancer immunotherapy  
Speaker: S. Endres (Germany)  

14:20  Molecular pathways associated with immune modulation and thalidomide analogues  
Speaker: R. Chopra (USA)  

14:40  Proffered Paper: Maintenance therapy of metastatic colorectal carcinoma with the TLR-9 agonist MGN1703: Clinical and immunological predictive pretreatment factors of activity in the IMPACT trial  
Speaker: H.J. Schmoll (Germany)  

Speaker: M. Shevtsov (Russian Federation)  

Plenary Session: Cancer Immunology  
15:30 - 17:10  
Chair: T. Gajewski (USA)  
Chair: P. Romero (Switzerland)  

15:30  KEYNOTE LECTURE: Immunobiological properties of the human cancer stem cells  
Speaker: C. Maccalli (Italy)  

16:00  Bavituximab: A novel phosphatidylserine-targeting immunotherapy for the treatment of cancer  
Speaker: J. Shan (USA)  

16:20  Targeting the myeloma microenvironment with immunotherapy  
Speaker: I. Borrello (USA)  

16:40  BiTe antibodies: from ex vivo models to clinical application in solid tumours  
Speaker: P. Kufer (Germany)  

17:00  Proffered Paper: Identification of novel immune checkpoints as targets for cancer immunotherapy  
Speaker: G. Cojocaru (Israel)
Poster Session: Monitoring of Immunotherapy

17:15 - 18:45

Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T cell and B cell responses but improves clinical efficacy in a murine pancreatic carcinoma model
Poster: C. Bauer (Germany)

Developing an immunotherapy strategy for the effective treatment of patients with non small cell lung cancer (NSCLC): Strategies to evaluate immunity in patients on clinical trials
Poster: M. Neuberger (Germany)

Combination of radiotherapy and chemotherapy with dendritic cell immunotherapy in glioblastoma patients induces NK and NKT cell responses
Poster: S. Pellegatta (Italy)

Intra-tumoral and surrogate immune responses in patients treated with the engineered anti-PD-L1 antibody (MPDL3280A)
Poster: M. Kowanetz (USA)

Poster Session: Immunomodulation

17:15 - 18:45

Cell-based gene delivery leverages conventional immunotherapy for cancer
Poster: C. Gunther (Germany)

A genetic mouse model to identify the role of the immune adapter protein MyD88 in colorectal cancer
Poster: A. Holterf (Germany)

Differential susceptibility of human and mouse NK cells to malignant cell-induced abnormalities in autologous combinations: A potential mechanism for the NK cell-based immunotherapy efficacy
Poster: G. Sconocchia (Italy)

RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells
Poster: M. Schnurr (Germany)
The tumour leukocyte infiltrate is the key predictor for therapeutic response to catumaxomab therapy
Poster: B. Mayer (Germany)

Immunomodulation of blasts in AML-Patients (pts) with clinically approved response modifiers to improve antileukaemic T-cell reactivity: An ex vivo simulation of the clinical situation
Poster: H. Schmetzer (Germany)

Lack of T cell exhaustion in acute myeloid leukaemia
Poster: F. Schmerfeil (Germany)

NK-cell dysfunction in human renal carcinoma reveals diacylglycerol kinase as key regulator and target for therapeutic intervention
Poster: P. Prinz (Germany)

Immunomodulation induced by resveratrol or genistein on proliferation and apoptosis of tumour colon cells
Poster: L.I. Brasoveanu (Romania)

Efficient ex vivo lysis of acute myeloid leukaemic (AML) cells mediated by triplebodies with dual-targeting capability in conjunction with natural killer cells as effectors
Poster: G. Fey (Germany)

Aviscumine enhances NK-cytotoxicity against tumor cells
Poster: G. Gamerith (Austria)

Poster Session: Other

17:15 - 18:45

Access to diagnostics: A bottleneck for immunotherapeutics development - case example of MAGE-A3 cancer immunotherapeutic
Poster: K. Lykopoulos (United Kingdom)

Cancer associated fibroblasts contribute to the immune suppression of breast cancer by augmentation of the inflammatory products
Poster: L. Langroudi (Iran)

Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
Poster: S. Eketorp Sylvan (Sweden)

Efficient CD19-positive leukaemia cell lysis mediated by a T cell-recruiting triplebody a[19-3-19]
Poster: C. Roskopf (Germany)
T-cell responses to oncopgenic Merkel cell polyomavirus proteins distinguish Merkel cell carcinoma patients from healthy donors
Poster: S.R. Hadrup (Denmark)

The use of HER2 receptors status as a prognostic index for estrogen receptor positive breast cancer patients
Poster: A. Tawfeek (Iraq)

Genomic profiling and functional characterisation of a new myeloid cell type enriched in renal cell carcinoma
Poster: D. Brech (Germany)

High resolution mass spectrometry reveals the depth and diversity of HLA-I peptidomes
Poster: M. Bassani-Sternberg (Germany)

NK-92 cellular immunotherapy as an alternative to donor derived peripheral blood NK cells
Poster: H. Klingemann (USA)

Thursday 13 March 2014

Plenary Session: Targeting Immune Suppression

08:30 - 10:00 Auditorium

Chair: D.J. Schendel (Germany)
Chair: S. Khleif (USA)

08:30 **KEYNOTE LECTURE: Regulatory T cells and suppression of immune response**
Speaker: J.P. Allison (USA)

09:00 **Therapeutic strategies based on overcoming immune resistance mechanisms within the melanoma tumour microenvironment**
Speaker: T. Gajewski (USA)

09:20 **Investigating the ICOS/ICOSL pathway as a target for combination therapy with anti-CTLA-4**
Speaker: P. Sharma (USA)

09:40 **Inhibition of indoleamine-2,3-dioxygenase (IDO)- mediated tumour immune escape**
Speaker: C. Opitz (Germany)
Plenary Session: Stimulation of Immune Function

10:30 - 12:10  Auditorium

Chair: L. Zitvogel (France)
Chair: A. Dalgleish (United Kingdom)

10:30  Many reasons for combining immunotherapy with chemotherapy to enhance anti tumour response  
Speaker: A. Dalgleish (United Kingdom)  

10:50  Role of gut microbiota in the anticancer effects of cytotoxic drugs  
Speaker: L. Zitvogel (France)  

11:10  Rationales, current and future for combination of immuno oncology therapies  
Speaker: A. Korman (USA)  

11:30  Oncolytic herpes simplex virus encoding GM-CSF for melanoma therapy  
Speaker: M. Urosevic-Maiwald (Switzerland)  

11:50  Novel CEA-targeted IL2 variant immunocytokine for immunotherapy of cancer  
Speaker: C. Klein (Switzerland)  

Satellite Symposium: Cancer immunotherapy: changing treatment paradigms in oncology

13:00 - 14:00  Auditorium

13:00  Welcome and Introduction  
Chair: I. Melero (USA)  

13:10  Exploring the evolving landscape of cancer immunotherapy  
Speaker: I. Melero (USA)  

13:25  From innovative science to clinical trials  
Speaker: E. Cha (USA)  

13:40  Future approaches to cancer immunotherapy  
Speaker: C. Klein (Switzerland)  

13:55  Close  
Chair: I. Melero (USA)
Plenary Session: Therapeutic Anti-Cancer Vaccines

14:00 - 15:30  
Auditorium

Chair: D.J. Schendel (Germany)  
Chair: S. Endres (Germany)

14:00  KEYNOTE LECTURE: Vaccine development  
Speaker: S. Khleif (USA)  

14:30  Dendritic cell vaccination combined with CTLA4 blockade  
Speaker: K. Thielemans (Belgium)

14:50  Role of CD40 activation in anti-tumour vaccine efficacy  
Speaker: C.J.M. Melief (Netherlands)

15:10  mRNA-based cancer vaccines  
Speaker: K. Kallen (Germany)

Plenary Session: Monitoring of Immunotherapy

16:00 - 17:30  
Auditorium

Chair: L. Hakansson (Sweden)  
Chair: B. Fox (USA)

16:00  Immune response parameters  
Speaker: L. Hakansson (Sweden)

16:20  Tumour infiltrating lymphoctes - a predictive marker?  
Speaker: J. Galon (France)

16:40  Biomarker development for ipilimumab and prostate GVAX treatment  
Speaker: T. De Gruijl (Netherlands)

17:00  Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A  
Speaker: E. Cha (USA)

17:20  Proffered Paper: Complex tumour microenvironment screening platform captures biological responses of cancer therapeutics  
Speaker: H. Layman (USA)
Poster Session: Vaccines

17:30 - 19:00

Identification of prostate cancer-associated antigens by oxygen manipulation
Poster: T. Ma (USA)

A new pathway of tumour antigen loading of human dendritic cells via intercellular communication
Poster: G. Penna (Italy)

Effect of lymphodepletion and tumour on host and reconstituted regulatory T-cells in a model of murine melanoma
Poster: J. Kovacs (Germany)

Possible role of MDSC for the induction of tumour-specific T cells following LRAST
Poster: P. Rose (Germany)

Dendritic cell vaccination for postremission therapy in AML
Poster: F. Lichtenegger (Germany)

A novel cancer vaccine with nanogel-based antigen transporter and sequence-optimised long peptide antigen
Poster: N. Harada (Japan)

Activation of RIG-I induces immunogenic cell death
Poster: S. Bek (Germany)

Poster Session: Immunocytokines

17:30 - 19:00

Can T-cells predict response to intravesical BCG immunotherapy in high-risk non-invasive bladder cancer
Poster: S. Jallad (United Kingdom)
Poster Session: Combination therapy

17:30 - 19:00

Depleting the suppressors for the benefit of immunotherapy against cervical cancer
Poster: O. Draghiciu (Netherlands)

Microtubule-depolymerising agents used in antibody-drug-conjugates induce anti-tumour immunity by stimulation of dendritic cells
Poster: K. Martin (Switzerland)

Evaluation of p21 promoter for radiation induced transcriptional targeting of interleukin 12 gene therapy
Poster: U. Kamensek (Slovenia)

Effetiveness of melatonin, IL-25 and siRNA IL-17B in growth control of breast cancer cell lines
Poster: G. Bottaro Gelaleti (Brazil)

Poster Session: Adoptive Immunotherapy

17:30 - 19:00

Autologous tumour cells and SW742 allogeneic cell line have comparable stimulating effect on PBMCs of gastrointestinal malignant patients in vitro
Poster: A. Sheikhi (Iran)

T cell re-direction against Glypican-3 for immunotherapy of hepatocellular carcinoma
Poster: C. Dargel (Germany)

Minor-histocompatibility-antigen UTY as target for graft-versus-leukaemia and graft-versus-haematopoiesis in the canine-model
Poster: D. Bund (Germany)

Generating and characterising WT1-specific T cells – research towards adoptive tumour therapy
Poster: S. Schmied (Germany)

Targeted natural killer (NK) cell based adoptive immunotherapy for the treatment of patients with non-small cell lung cancer (NSCLC) after radiochemotherapy (RCT) – clinical application of NK cells activated by heat shock protein 70 (Hsp70)
Poster: H. Specht (Germany)
Poster Session: Engineered T-cell therapy

17:30 - 19:00

**A new EGFR - EpCAM bispecific antibody enhances the efficacy of adoptive T-cell therapy in a murine gastric tumour model**
Poster: S. Kobold (Germany)

**Targeting naturally presented, leukemia-derived HLA ligands with TCR-transgenic T cells for the treatment of therapy refractory leukemias**
Poster: R. Klar (Germany)

**Development of clinically implementable imaging strategies for tracking T cell receptor-transgenic T cells**
Poster: S. Mall (Germany)

**Adoptive transfer of TCR gene-transduced lymphocytes targeting MAGE-A4 for refractory esophageal cancer**
Poster: H. Shiku (Japan)

**Transgenic expression of a chimeric signaling receptor to facilitate T cell costimulation in the tumour environment**
Poster: R. Schlenker (Germany)

**Functional characterisation of HBV-specific T cell receptors for redirection of T cells against HBV infected hepatocytes**
Poster: K. Krebs (Germany)

**A Good Manufacturing Practice procedure to generate therapeutic numbers of highly pure anti-leukaemic virus-specific T-cells**
Poster: M. Van Loenen (Netherlands)

**Genetic engineering of T cells for increased homing to the tumor site**
Poster: M. Idorn (Denmark)
Friday 14 March 2014

Plenary Session: Adoptive Cell Therapy

08:30 - 10:00 Auditorium

Chair: F. Marincola (Qatar)

08:30 **KEYNOTE LECTURE:** Basic concept for the understanding of cancer mediated immune rejection
Speaker: F. Marincola (Qatar) $75

09:00 **Adoptive cell therapy of melanoma with autologous tumour infiltrating lymphocytes**
Speaker: I.M. Svane (Denmark) $76

09:20 **Autologous cellular immunotherapy for prostate cancer**
Speaker: G. Perez de Lema (USA)

09:40 **Proffered Paper: In vitro induced response patterns of antileukemic T-cells – characterization by combination of functional assays, spectratyping and next generation sequencing**
Speaker: S. Reuther (Germany) $77

09:50 **Proffered Paper: High-affinity CD20-specific TCRs suitable for adoptive immunotherapy can be readily isolated from the allo-repertoire using reverse immunology**
Speaker: L. Jahn (Netherlands) $78

Plenary Session: Engineered T Cell Therapy

10:30 - 12:00 Auditorium

Chair: A. Shen (USA)
Chair: R. Hawkins (United Kingdom)

10:30 **CAR strategies in solid tumours**
Speaker: C. Rossig, ‘’ (Germany) $79

11:00 **Prolongation of T cell response by OX40 co-signalling CARS**
Speaker: H. Abken (Germany) $80
11:20 Proffered Paper: A new PD1-CD28 chimeric receptor overcomes PD-1-mediated immunosuppression in adoptive T cell therapy
Speaker: S. Kobold (Germany)

11:40 Proffered Paper: In-vivo testing of PSMA-targeted T-cell immunotherapy for prostate cancer
Speaker: Z. Liu (United Kingdom)

Plenary Session: Closing Remarks

12:00 - 12:30 Auditorium

Closing remarks
Speaker: V. Nussler (Germany)

Poster Award Presentation
Speaker: H. Hendriks (Netherlands)